FXYD1抗体

+ +

•  

   

     Gel: 12%SDS-PAGE, Lysate: 40 μg, Lane 1-2: Mouse brain tissue, Mouse heart tissue, Primary antibody: P01079(FXYD1 Antibody) at dilution 1/1290, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 1 second    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human tonsil tissue using P01079(FXYD1 Antibody) at dilution 1/60. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human brain  tissue using P01079(FXYD1 Antibody) at dilution 1/60. (Original magnification: ×200)    

  
  

**Background of FXYD1 Antibodies**

FXYD1. also known as phospholemman, is a small transmembrane protein that regulates the activity of the Na+/K+-ATPase pump, a critical enzyme responsible for maintaining cellular ion gradients. It belongs to the FXYD protein family, which modulates ion transport in a tissue-specific manner. FXYD1 is highly expressed in the heart, skeletal muscle, and brain, where it fine-tunes sodium and potassium ion flux, impacting cellular excitability and osmotic balance. Its activity is further influenced by post-translational modifications, such as phosphorylation, which alter its interaction with the Na+/K+-ATPase.

Antibodies targeting FXYD1 are essential tools for studying its expression, localization, and functional roles in physiological and pathological contexts. These antibodies are commonly used in techniques like Western blotting, immunohistochemistry, and immunofluorescence to assess FXYD1 protein levels and distribution in tissues or cells. Researchers employ FXYD1-specific antibodies to investigate its involvement in diseases such as heart failure (where FXYD1 dysregulation affects cardiac contractility), cancer (linked to ion homeostasis and cell proliferation), and metabolic disorders. Both monoclonal and polyclonal FXYD1 antibodies are available, with validation including knockout controls or peptide-blocking assays to confirm specificity. Understanding FXYD1's role through antibody-based research continues to shed light on its regulatory mechanisms and therapeutic potential.